Generate Biomedicines, Inc. (GENB) Stock Statistics & Valuation Metrics

Generate Biomedicines, Inc. has a market cap or net worth of $1.75B. The enterprise value is $1.72B.

Generate Biomedicines, Inc. has 128,192,490 shares outstanding. The number of shares has decreased by -2.65% in one year.

Generate Biomedicines, Inc.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is -89.38%.

The current PE Ratio of Generate Biomedicines, Inc. is ―. Generate Biomedicines, Inc.’s PEG ratio is -0.01.

In the last 12 months, Generate Biomedicines, Inc. had revenue of 31.89M and earned -203.15M in profits. Earnings per share was -4.98.

In the last 12 months, operating cash flow was -80.39M and capital expenditures -3.78M, giving a free cash flow of -84.17M billion.

Generate Biomedicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Generate Biomedicines, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Generate Biomedicines, Inc. as a current ratio of 2.85, with Debt / Equity ratio of -11.12%

In the past 12 months, Generate Biomedicines, Inc. has paid 163.00K in taxes.

Generate Biomedicines, Inc. EV to EBITDA ratio is -2.78, with an EV/FCF ratio of -2.84.

Generate Biomedicines, Inc. has $516.64M in cash and marketable securities with $65.57M in debt, giving a net cash position of $451.07M billion.

Gross margin is 100.00%, with operating margin of -737.04%, and net profit margin of -636.99%.

The average price target for Generate Biomedicines, Inc. is $25.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy